Quebec Terry2™ Registry Demonstrates Near-Zero Radial Artery Occlusion
- 4 hours ago
- 1 min read
Nanostent announces the publication of the Quebec Terry2™ Registry in Catheterization & Cardiovascular Interventions Journal. https://doi.org/10.1002/ccd.70511
In this prospective registry of 578 patients, led by Dr. T. Cieza at Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ), Dr. F. Bonnenfant at Hôpital Chicoutimi, and Dr. J. MacHaalany at Hôtel Dieu de Québec, the Terry2™ radial hemostasis device demonstrated:
100% patent hemostasis
0.2% radial artery occlusion (RAO) at 30 days
92% very high patient comfort
Hemostasis in approximately 2 hours for most patients
Compared with published RAO rates of 10–30% at discharge using conventional devices, Terry2™ delivers dramatically improved vessel preservation.
By combining prophylactic ulnar compression with non-occlusive radial hemostasis, Terry2™ enables reliable artery patency, faster hospital discharge, and over 10–15 minutes saved per patient in nursing time.
In an era of staffing shortages and increasing procedure volumes, Terry2™ offers both clinical excellence and operational efficiency.
Nanostent is currently preparing to launch Terry2™ in Canada and other international markets while continuing to collaborate with radial approach experts in clinical research.
For more information, please contact us
Comments